SEC Tracker
Get the app

Zenas BioPharma ZBIO

Zenas BioPharma terminates stock offering

Securities offering

Form
424B5
Filed
Importance
Routine
  1. Up to $200,000,000 in common stock offered
  2. Sold $153.2 million under prior offering
  3. Terminating offering, no further sales planned
  4. Jefferies LLC as sales agent with 3.0% commission

Written from the 424B5 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Zenas BioPharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025
  2. Verastem VSTM public float $254M, Jun 30, 2025
  3. Corvus Pharmaceuticals CRVS public float $252M, Jun 30, 2025
  4. DBV Technologies DBVT public float $251M, Jun 30, 2025
  5. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.